Benjamin Djulbegovic I-3661-2012

Benjamin Djulbegovic, MD DSC

Distinguish Prof & Assoc Dean, Comparative Effectiveness Research

Professor, Department of Oncologic Sciences

Associate Dean, College of Medicine Internal Medicine

Distinguished Professor, Internal Medicine, Morsani College of Medicine

Director, USF Center for Evidence-Based Medicine and Health Outcome Research

Professor, Medicine and Oncology

Director, Evidence-Based Medicine Research Group

Professor, College of Medicine Internal Medicine

Contact Info Division of Evidence Based Medicine
3515 East Fletcher Avenue, MDC 27
Tampa FL 33612

Academic Email: bdjulbeg@health.usf.edu

Academic Phone:(813) 396-9178

View My C.V.

Education

  • DSC, University of Sarajevo, 1987
  • M.Sc., Biophysics, University of Zagreb, 1980
  • MD, University of Sarajevo, 1976

Research Interests

  • Benjamin Djulbegovic is a Distinguished Professor and Professor of Medicine and Oncology at the University of South Florida. His major academic research interest lies in the area of evidence-based medicine, decision-analysis, clinical reasoning, systematic reviews /meta-analysis and comparative effectiveness research, ethics and design of clinical trials, practice guidelines, outcomes research, impact of clinical trials and the role of uncertainty in medicine. He has extensively published and taught on these subjects. His work on regret in decision-making and the role of uncertainty in the conduct of clinical trials received national and international rewards and has received attention of the press all over the world. Dr. Djulbegovic’s research has been funded both by private entities and the NIH.

Memberships

  • American College of Physicians (Member, 2008 - Present)
  • American Society of Hematology (Member, 2008 - Present)
  • American Society of Clinical Oncology (Member, 2008 - Present)
  • American Medical Association (Member, 2008 - Present)
  • Society for Medical Decision Making (Member, 2008 - Present)
  • Jefferson County Medical Society (Member, 2008 - Present)
  • Florida Medical Association (Member, 2008 - Present)
  • American Association for the Advancement of Science (Member, 2008 - Present)

Recent Publications

  • Tsalatsanis A, Hozo I, Djulbegovic B. Acceptable regret model in the end-of-life setting: Patients require high level of certainty before forgoing management recommendations. European journal of cancer (Oxford, England : 1990). 75: 159-166, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28235727
  • Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. Lancet (London, England). 390(10092) : 415-423, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28215660
  • Reljic T, Kumar A, Klocksieben FA, Djulbegovic B. Treatment targeted at underlying disease versus palliative care in terminally ill patients: a systematic review. BMJ open. 7(1) : e014661, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28062473
  • Hozo I, Tsalatsanis A, Djulbegovic B. Monte Carlo decision curve analysis using aggregate data. European journal of clinical investigation. 47(2) : 176-183, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28042671
  • Dahm P Oxman AD Djulbegovic B Guyatt GH et al. Applying GRADE to Coverage Decisions: Results of a Stakeholder Survey and Workshop. J Clin Epidemiol.. : pii: S0895-4356(17)30335-9. doi: 10.1016/j.jclinepi.2017.02.019. [Epub ahead of print], 2017.
  • Hozo I, Djulbegovic B, Luan S, Tsalatsanis A, Gigerenzer G. Towards theory integration: Threshold model as a link between signal detection theory, fast-and-frugal trees and evidence accumulation theory. Journal of evaluation in clinical practice. 23(1) : 49-65, 2017. http://www.ncbi.nlm.nih.gov/pubmed/26683386
  • Djulbegovic B, Tsalatsanis A, Hozo I. Determining optimal threshold for statins prescribing: individualization of statins treatment for primary prevention of cardiovascular disease. Journal of evaluation in clinical practice. 23(2) : 241-250, 2017. http://www.ncbi.nlm.nih.gov/pubmed/26555150
  • Djulbegovic B, Elqayam S. Many faces of rationality: Implications of the great rationality debate for clinical decision-making. Journal of evaluation in clinical practice. , 2017. http://www.ncbi.nlm.nih.gov/pubmed/28730671
  • Mayrhofer T, Hamm RM, Van den Ende J, Hozo I, Djulbegovic B. The predicament of patients with suspected Ebola. The Lancet. Global health. 5(7) : e657, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28619222
  • Dahm P, Oxman AD, Djulbegovic B, Guyatt GH, Murad MH, Amato L, Parmelli E, Davoli M, Morgan RL, Mustafa RA, Sultan S, Falck-Ytter Y, Akl EA, Schünemann HJ. Stakeholders apply the GRADE evidence-to-decision framework to facilitate coverage decisions. Journal of clinical epidemiology. 86: 129-139, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28377194
  • Bennett CL, Djulbegovic B. Thrombotic thrombocytopenic purpura: gaining knowledge. The Lancet. Haematology. 3(5) : e210-1, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27132693
  • Urrútia G, Ballesteros M, Djulbegovic B, Gich I, Roqué M, Bonfill X. Cancer randomized trials showed that dissemination bias is still a problem to be solved. Journal of clinical epidemiology. 77: 84-90, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27164275
  • Martinez DA, Tsalatsanis A, Yalcin A, Zayas-Castro JL, Djulbegovic B. Activating clinical trials: a process improvement approach. Trials. 17(1) : 106, 2016. http://www.ncbi.nlm.nih.gov/pubmed/26907923
  • Kumar A, Miladinovic B, Guyatt GH, Schünemann HJ, Djulbegovic B. GRADE guidelines system is reproducible when instructions are clearly operationalized even among the guidelines panel members with limited experience with GRADE. Journal of clinical epidemiology. 75: 115-8, 2016. http://www.ncbi.nlm.nih.gov/pubmed/26845745
  • Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. The Cochrane database of systematic reviews. 2: CD009624, 2016. http://www.ncbi.nlm.nih.gov/pubmed/26845108
  • Alexander PE, Brito JP, Neumann I, Gionfriddo MR, Bero L, Djulbegovic B, Stoltzfus R, Montori VM, Norris SL, Schünemann HJ, Guyatt GH. World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance. Journal of clinical epidemiology. 72: 98-106, 2016. http://www.ncbi.nlm.nih.gov/pubmed/25618534
  • Hozo I, Tsalatsanis A, Djulbegovic B. Expected utility versus expected regret theory versions of decision curve analysis do generate different results when treatment effects are taken into account. Journal of evaluation in clinical practice. , 2016. http://www.ncbi.nlm.nih.gov/pubmed/27981695
  • Djulbegovic B, Tsalatsanis A, Mhaskar R, Hozo I, Miladinovic B, Tuch H. Eliciting regret improves decision making at the end of life. European journal of cancer (Oxford, England : 1990). 68: 27-37, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27710829
  • Mhaskar R, Miladinovic B, Guterbock TM, Djulbegovic B. When are clinical trials beneficial for study patients and future patients? A factorial vignette-based survey of institutional review board members. BMJ open. 6(9) : e011150, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27683511
  • Guyatt GH, Alonso-Coello P, Schünemann HJ, Djulbegovic B, Nothacker M, Lange S, Murad MH, Akl EA. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. Journal of clinical epidemiology. 80: 3-7, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27452192
  • Alexander PE, Gionfriddo MR, Li SA, Bero L, Stoltzfus RJ, Neumann I, Brito JP, Djulbegovic B, Montori VM, Norris SL, Schünemann HJ, Thabane L, Guyatt GH. A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. Journal of clinical epidemiology. 70: 111-22, 2016. http://www.ncbi.nlm.nih.gov/pubmed/26399903
  • Alexander PE, Li SA, Gionfriddo MR, Stoltzfus RJ, Neumann I, Brito JP, Djulbegovic B, Montori VM, Schünemann HJ, Guyatt GH. Senior GRADE methodologists encounter challenges as part of WHO guideline development panels: an inductive content analysis. Journal of clinical epidemiology. 70: 123-8, 2016. http://www.ncbi.nlm.nih.gov/pubmed/26385188
  • Cucchetti A, Djulbegovic B. Reply. Hepatology (Baltimore, Md.). 63(3) : 1051, 2016. http://www.ncbi.nlm.nih.gov/pubmed/25976950
  • Mhaskar R & Djulbegovic B. Iron for treatment of chemotherapy-induced anemia in cancer 18 patients receiving erythropoiesis-stimulating agents. JAMA Onc. : doi: 10.1001/jamaoncol.2016.1864. [Epub ahead of print] [PMID: 27387766], 2016.
  • Bennett CL & Djulbegovic B. Thrombotic thrombocytopenia purpura: gaining knowledge. Lancet Haematology. 3(5) : e210-1. doi: 10.1016/S2352-3026(16)30028-X [PMID: 27132693], 2016.
  • Mhaskar R, Djulbegovic B. Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents. JAMA oncology. 2(11) : 1499-1500, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27387766
  • Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. Journal of the National Comprehensive Cancer Network : JNCCN. 14(4) : 389-400, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27059188
  • Djulbegovic B. Value-based Cancer Care and the Excessive Cost of Drugs. JAMA One. 1(9) : 1301-2, 2015.
  • Schully SD, Lam TK, Dotson WD, Chang CQ, Aronson N, Birkeland ML, Brewster SJ, Boccia S, Buchanan AH, Calonge N, Calzone K, Djulbegovic B, Goddard KA, Klein RD, Klein TE, Lau J, Long R, Lyman GH, Morgan RL, Palmer CG, Relling MV, Rubinstein WS, Swen JJ, Terry SF, Williams MS, Khoury MJ. Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genetics in medicine : official journal of the American College of Medical Genetics. 17(1) : 63-7, 2015. http://www.ncbi.nlm.nih.gov/pubmed/24946156
  • Djulbegovic B Hamm RM Mayerhofer T Hozo I van den Ende J. Rationality, Practice Variation, and Person-Centered Health Policy: a Threshold Hypothesis. J Eval Clin Pract. , 2015.
  • Gil-Herrera E Aden-Buie G Yalcin A Tsalatsanis A Barnes LE and Djulbegovic B. Rough set theory based prognostic classification models for hospice referral. BMC Medical Informatics and Decision Making. 15(98) , 2015.
  • Alexander PE Gionfriddo MR Li SA Bero L Stoltzfus R Neumann I Britto JP Djulbegovic B Montori VM Norris SLSchünemann HJ Thabane L Guyatt GH. A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. J Clin Epidemiol. , 2015.
  • Alexander PE Li SA Gionfriddo MR Stoltzfus R Neumann I Britto JP Djulbegovic B Montori VM Schünemann HJ Guyatt GH. Senior GRADE methodologists encounter challenges as part of WHO guideline development panels: an inductive content analysis. J Clin Epidemiol. 70: 123-8, 2015.
  • Djulbegovic M Beckstead J Elqayam S Reljic T Kumar A Paidas C Djulbegovic B. Thinking styles & regret in physicians. PLos One. 10(8) : e0134038, 2015.
  • Tsalatsanis A Hozo I Kumar A Djulbegovic B. Dual processing model for medical decision-making: An extension to diagnostic testing. PLoS ONE. 10(8) : e0134800, 2015.
  • Price AI Djulbegovic B Biswas R Chatarjee P. Evidence-based medicine meets person centered care: a collaborative perspective on the relationship. J Eval Clin Practice. 21(6) : 1047-51, 2015.
  • Djulbegovic B van den Ende J Hamm RM Mayrhofer T Hozo I Pauker SG. When is rational to order a diagnostic test, or prescribe treatment: the threshold model as an explanation of practice variation. Eur J Clin Invest.. 45(5) : 485-93, 2015.
  • Djulbegovic B Kumar A Kaufman RM Tobian A Guyatt GH. Quality of evidence is a key determinant for making a strong GRADE guidelines recommendation. J Clin Epidemiol. 68(7) : 727-32, 2015.
  • Mhaskar R, Pathak EB, Wieten S, Guterbock TM, Kumar A, Djulbegovic B. Those Responsible for Approving Research Studies Have Poor Knowledge of Research Study Design: a Knowledge Assessment of Institutional Review Board Members. Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH. 23(4) : 196-201, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26483590
  • Reljic T, Kumar A, Djulbegovic B, Kharfan-Dabaja MA. High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review. Bone marrow transplantation. 50(8) : 1144, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26242579
  • Mahipal A, Denson AC, Djulbegovic B, Lush R, Kumar A, Juan TH, Schell MJ, Sullivan DM. Effect of Age on Clinical Outcomes in Phase 1 Trial Participants. Cancer control : journal of the Moffitt Cancer Center. 22(2) : 235-41, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26068771
  • Djulbegovic B, Hozo I, Ioannidis J. Modern health care as a game theory problem: reply. European journal of clinical investigation. 45(4) : 443, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25630659
  • Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 13(11) : 1398-435, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26553768
  • Djulbegovic B, Hamm RM, Mayrhofer T, Hozo I, Van den Ende J. Rationality, practice variation and person-centred health policy: a threshold hypothesis. Journal of evaluation in clinical practice. 21(6) : 1121-4, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26639018
  • Gil-Herrera E, Aden-Buie G, Yalcin A, Tsalatsanis A, Barnes LE, Djulbegovic B. Rough set theory based prognostic classification models for hospice referral. BMC medical informatics and decision making. 15: 98, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26606986
  • Price AI, Djulbegovic B, Biswas R, Chatterjee P. Evidence-based medicine meets person-centred care: a collaborative perspective on the relationship. Journal of evaluation in clinical practice. 21(6) : 1047-51, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26358758
  • Djulbegovic B. Value-Based Cancer Care and the Excessive Cost of Drugs. JAMA oncology. 1(9) : 1301-2, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26313294
  • Tsalatsanis A, Hozo I, Kumar A, Djulbegovic B. Dual Processing Model for Medical Decision-Making: An Extension to Diagnostic Testing. PloS one. 10(8) : e0134800, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26244571
  • Djulbegovic M, Beckstead J, Elqayam S, Reljic T, Kumar A, Paidas C, Djulbegovic B. Thinking Styles and Regret in Physicians. PloS one. 10(8) : e0134038, 2015. http://www.ncbi.nlm.nih.gov/pubmed/26241650
  • Reljic T, Kumar A, Djulbegovic B, Kharfan-Dabaja MA. High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review. Bone marrow transplantation. 50(8) : 1069-74, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25867647
  • Djulbegovic B, Kumar A, Kaufman RM, Tobian A, Guyatt GH. Quality of evidence is a key determinant for making a strong GRADE guidelines recommendation. Journal of clinical epidemiology. 68(7) : 727-32, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25766057
  • Djulbegovic B, van den Ende J, Hamm RM, Mayrhofer T, Hozo I, Pauker SG. When is rational to order a diagnostic test, or prescribe treatment: the threshold model as an explanation of practice variation. European journal of clinical investigation. 45(5) : 485-93, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25675907
  • Guyatt GH, Schünemann HJ, Djulbegovic B, Akl EA. Guideline panels should not GRADE good practice statements. Journal of clinical epidemiology. 68(5) : 597-600, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25660962
  • Djulbegovic B, Hozo I, Ioannidis JP. Modern health care as a game theory problem. European journal of clinical investigation. 45(1) : 1-12, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25413314
  • Kumar A, Mhaskar R, Grossman BJ, Kaufman RM, Tobian AA, Kleinman S, Gernsheimer T, Tinmouth AT, Djulbegovic B. Platelet transfusion: a systematic review of the clinical evidence. Transfusion. 55(5) : 1116-27; quiz 1115, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25387589
  • Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, Cipolle MD, Cohn CS, Fung MK, Grossman BJ, Mintz PD, O'Malley BA, Sesok-Pizzini DA, Shander A, Stack GE, Webert KE, Weinstein R, Welch BG, Whitman GJ, Wong EC, Tobian AA. Platelet transfusion: a clinical practice guideline from the AABB. Annals of internal medicine. 162(3) : 205-13, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25383671
  • Cucchetti A, Djulbegovic B, Tsalatsanis A, Vitale A, Hozo I, Piscaglia F, Cescon M, Ercolani G, Tuci F, Cillo U, Pinna AD. When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology (Baltimore, Md.). 61(3) : 905-14, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25048515
  • Hozo I Djulbegovic B Luan S Tsalatsanis A Gigerenzer G. Towards theory integration: threshold model as a link between signal-detection theory, fast-and-frugal trees and evidence accumulation theory. J Eval Clin Practice. , 2015.
  • Gil-Herrera E, Tsalatsanis A, Kumar A, Mhaskar R, Miladinovic B, Yalcin A, Djulbegovic B. Identifying homogenous subgroups for individual patient meta-analysis based on Rough Set Theory. Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference. 2014: 3434-7, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25570729
  • Djulbegovic B, Beckstead JW, Elqayam S, Reljic T, Hozo I, Kumar A, Cannon-Bowers J, Taylor S, Tsalatsanis A, Turner B, Paidas C. Evaluation of Physicians' Cognitive Styles. Medical decision making : an international journal of the Society for Medical Decision Making. 34(5) : 627-37, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24722474
  • . The EGAPP initiative: lessons learned. Genetics in medicine : official journal of the American College of Medical Genetics. 16(3) : 217-24, 2014. http://www.ncbi.nlm.nih.gov/pubmed/23928914
  • Alexander PE, Bero L, Montori VM, Brito JP, Stoltzfus R, Djulbegovic B, Neumann I, Rave S, Guyatt G. World Health Organization recommendations are often strong based on low confidence in effect estimates. Journal of clinical epidemiology. 67(6) : 629-34, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24388966
  • Hernandez JM, Tsalatsanis A, Humphries LA, Miladinovic B, Djulbegovic B, Velanovich V. Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis. Annals of surgery. 259(6) : 1208-14, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24169177
  • Mhaskar RS, Reljic T, Wao H, Kumar A, Miladinovic B, Djulbegovic B. Treatment-related harms: what was planned and what was reported? National Cancer Institute's Co-operative group phase III randomized controlled trials: a systematic review. Journal of clinical epidemiology. 67(3) : 354-6, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24055164
  • Reljic T, Mahony H, Djulbegovic B, Etchason J, Paxton H, Flores M, Kumar A. Value of repeat head computed tomography after traumatic brain injury: systematic review and meta-analysis. Journal of neurotrauma. 31(1) : 78-98, 2014. http://www.ncbi.nlm.nih.gov/pubmed/23914924
  • Djulbegovic B, Hozo I, Ioannidis JP. Improving the drug development process: more not less randomized trials. JAMA. 311(4) : 355-6, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24449311
  • Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, Howells DW, Ioannidis JP, Oliver S. How to increase value and reduce waste when research priorities are set. Lancet (London, England). 383(9912) : 156-65, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24411644
  • Mhaskar R, Clark OA, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. The Cochrane database of systematic reviews. (10) : CD003039, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25356786
  • Miladinovic B, Kumar A, Mhaskar R, Djulbegovic B. Benchmarks for detecting 'breakthroughs' in clinical trials: empirical assessment of the probability of large treatment effects using kernel density estimation. BMJ open. 4(10) : e005249, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25335959
  • Zhang Y, Tikkinen KA, Agoritsas T, Ayeni OR, Alexander P, Imam M, Yoo D, Tsalatsanis A, Djulbegovic B, Thabane L, Schünemann H, Guyatt GH. Patients' values and preferences of the expected efficacy of hip arthroscopy for osteoarthritis: a protocol for a multinational structured interview-based study combined with a randomised survey on the optimal amount of information to elicit preferences. BMJ open. 4(10) : e005536, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25326208
  • Djulbegovic B, Guyatt GH. Evidence-based practice is not synonymous with delivery of uniform health care. JAMA. 312(13) : 1293-4, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25268433
  • Djulbegovic B, Hozo I. Effect of initial conditions on reproducibility of scientific research. Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH. 22(3) : 156-9, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25132705
  • Mahony H, Tsalatsanis A, Kumar A, Djulbegovic B. Evolution of treatment regimens in multiple myeloma: a social network analysis. PloS one. 9(8) : e104555, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25119186
  • Wao H, Mhaskar R, Kumar A, Miladinovic B, Guterbock T, Hozo I, Djulbegovic B. Uncertainty about effects is a key factor influencing institutional review boards' approval of clinical studies. Annals of epidemiology. 24(10) : 734-40, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25108689
  • Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. The Cochrane database of systematic reviews. (7) : CD010280, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25061777
  • Pathak EB, Wieten S, Djulbegovic B. From hospice to hospital: short-term follow-up study of hospice patient outcomes in a US acute care hospital surveillance system. BMJ open. 4(7) : e005196, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25052170
  • Mhaskar RS, Wao H, Mahony H, Kumar A, Djulbegovic B. Concordance between decision analysis and matching systematic review of randomized controlled trials in assessment of treatment comparisons: a systematic review. BMC medical informatics and decision making. 14: 57, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25023450
  • Djulbegovic B, Elqayam S, Reljic T, Hozo I, Miladinovic B, Tsalatsanis A, Kumar A, Beckstead J, Taylor S, Cannon-Bowers J. How do physicians decide to treat: an empirical evaluation of the threshold model. BMC medical informatics and decision making. 14: 47, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24903517
  • Abu-Dalle I, Reljic T, Nishihori T, Antar A, Bazarbachi A, Djulbegovic B, Kumar A, Kharfan-Dabaja MA. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 20(11) : 1677-86, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24867779
  • Ioannidis JP, Hozo I, Djulbegovic B. Study design and the drug development process--reply. JAMA. 311(19) : 2023-4, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24846045
  • Djulbegovic B. A framework to bridge the gaps between evidence-based medicine, health outcomes, and improvement and implementation science. Journal of oncology practice. 10(3) : 200-2, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24839282
  • Djulbegovic B, Beckstead J, Nash DB. Human judgment and health care policy. Population health management. 17(3) : 139-40, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24835387
  • . Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes? Genetics in medicine : official journal of the American College of Medical Genetics. 16(4) : 338-46, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24071797
  • Han D, Zager JS, Shyr Y, Chen H, Berry LD, Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, Messina JL, Vetto JT, White RL, Pockaj B, Mozzillo N, Charney KJ, Avisar E, Krouse R, Kashani-Sabet M, Leong SP. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(35) : 4387-93, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24190111
  • . Recommendations from the EGAPP Working Group: does genomic profiling to assess type 2 diabetes risk improve health outcomes? Genetics in medicine : official journal of the American College of Medical Genetics. 15(8) : 612-7, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23492873
  • . Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genetics in medicine : official journal of the American College of Medical Genetics. 15(7) : 517-27, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23429431
  • Terasawa T, Trikalinos NA, Djulbegovic B, Trikalinos TA. Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis. Cancer treatment reviews. 39(4) : 340-9, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22703832
  • Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. British journal of haematology. 163(3) : 315-25, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24033280
  • Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. The Cochrane database of systematic reviews. (1) : CD004720, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23440794
  • Miladinovic B, Kumar A, Hozo I, Mahony H, Djulbegovic B. Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: a case study of meta-analyses of multiple myeloma trials. Contemporary clinical trials. 34(2) : 257-61, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23274403
  • Veenstra DL, Piper M, Haddow JE, Pauker SG, Klein R, Richards CS, Tunis SR, Djulbegovic B, Marrone M, Lin JS, Berg AO, Calonge N. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genetics in medicine : official journal of the American College of Medical Genetics. 15(1) : 14-24, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22955111
  • Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, Brozek J, Norris S, Meerpohl J, Djulbegovic B, Alonso-Coello P, Post PN, Busse JW, Glasziou P, Christensen R, Schünemann HJ. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. Journal of clinical epidemiology. 66(2) : 158-72, 2013. http://www.ncbi.nlm.nih.gov/pubmed/22609141
  • Miladinovic B, Mhaskar R, Kumar A, Kim S, Schonwetter R, Djulbegovic B. External validation of a web-based prognostic tool for predicting survival for patients in hospice care. Journal of palliative care. 29(3) : 140-6, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24380212
  • Patel J, Ho M, Ho V, Bello C, Djulbegovic B, Sokol L, Wetzstein G. Rapid infusion rituximab for maintenance therapy: is it feasible? Leukemia research and treatment. 2013: 629283, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24288618
  • Mhaskar R, B Bercu B, Djulbegovic B. At what level of collective equipoise does a randomized clinical trial become ethical for the members of institutional review board/ethical committees? Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH. 21(3) : 156-9, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24167382
  • Djulbegovic B, Kumar A, Glasziou P, Miladinovic B, Chalmers I. Medical research: Trial unpredictability yields predictable therapy gains. Nature. 500(7463) : 395-6, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23969443
  • Mhaskar R, Alandikar V, Emmanuel P, Djulbegovic B, Patel S, Patel A, Naik E, Mohapatra S, Kumar A. Adherence to antiretroviral therapy in India: a systematic review and meta-analysis. Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine. 38(2) : 74-82, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23878418
  • Djulbegovic B, Norris LB, Bennett CL. Colony-stimulating factors for febrile neutropenia. The New England journal of medicine. 369(3) : 286, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23863062
  • Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B. Sequence of novel agents in multiple myeloma: an instrumental variable analysis. Leukemia research. 37(9) : 1077-82, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23809054
  • Ioannidis JP, Hozo I, Djulbegovic B. Optimal type I and type II error pairs when the available sample size is fixed. Journal of clinical epidemiology. 66(8) : 903-910.e2, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23664493
  • El-Jurdi N, Reljic T, Kumar A, Pidala J, Bazarbachi A, Djulbegovic B, Kharfan-Dabaja MA. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy. 5(5) : 457-66, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23638742
  • Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, Rind D, Montori VM, Brito JP, Norris S, Elbarbary M, Post P, Nasser M, Shukla V, Jaeschke R, Brozek J, Djulbegovic B, Guyatt G. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. Journal of clinical epidemiology. 66(7) : 726-35, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23570745
  • Djulbegovic B, Kumar A, Miladinovic B, Reljic T, Galeb S, Mhaskar A, Mhaskar R, Hozo I, Tu D, Stanton HA, Booth CM, Meyer RM. Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. PloS one. 8(3) : e58711, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23555593
  • Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. The New England journal of medicine. 368(12) : 1131-9, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23514290
  • Miladinovic B, Mhaskar R, Hozo I, Kumar A, Mahony H, Djulbegovic B. Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error. Journal of clinical epidemiology. 66(6) : 654-9, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23403248
  • Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Systematic reviews. 2: 10, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23379753
  • Mann H, Djulbegovic B. Comparator bias: why comparisons must address genuine uncertainties. Journal of the Royal Society of Medicine. 106(1) : 30-3, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23358277
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R. Multiple myeloma, version 1.2013. Journal of the National Comprehensive Cancer Network : JNCCN. 11(1) : 11-7, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23307977
  • Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Journal of hematology & oncology. 6: 2, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23289975
  • Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, Holcomb JB, Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, Weinstein R, Swinton McLaughlin LG, Djulbegovic B. Red blood cell transfusion: a clinical practice guideline from the AABB*. Annals of internal medicine. 157(1) : 49-58, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22751760
  • Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, Raftery J, Johansen M, Di Tanna GL, Miladinovic B, Soares HP, Vist GE, Chalmers I. New treatments compared to established treatments in randomized trials. The Cochrane database of systematic reviews. 10: MR000024, 2012. http://www.ncbi.nlm.nih.gov/pubmed/23076962
  • Schroen AT, Petroni GR, Wang H, Thielen MJ, Gray R, Benedetti J, Wang XF, Sargent DJ, Wickerham DL, Cronin W, Djulbegovic B, Slingluff CL. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(1) : 256-62, 2012. http://www.ncbi.nlm.nih.gov/pubmed/21976533
  • Kumar A, Mhaskar AR, Reljic T, Mhaskar RS, Kharfan-Dabaja MA, Anasetti C, Mohty M, Djulbegovic B. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. 26(4) : 582-8, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22182922
  • Djulbegovic B, Hozo I, Beckstead J, Tsalatsanis A, Pauker SG. Dual processing model of medical decision-making. BMC medical informatics and decision making. 12: 94, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22943520
  • Djulbegovic M, Neuberger MM, Dahm P. Prostate-cancer mortality after PSA screening. The New England journal of medicine. 366(23) : 2228-9; author reply 2230-1, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22670914
  • La Caze A, Djulbegovic B, Senn S. What does randomisation achieve? Evidence-based medicine. 17(1) : 1-2, 2012. http://www.ncbi.nlm.nih.gov/pubmed/21693455
  • Djulbegovic B, Hozo I. When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt. BMC medical research methodology. 12: 85, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22726276
  • Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma: a network meta-analysis. The Cochrane database of systematic reviews. (5) : CD003188, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22592688
  • Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB. Cancer- and chemotherapy-induced anemia. Journal of the National Comprehensive Cancer Network : JNCCN. 10(5) : 628-53, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22570293
  • Kharfan-Dabaja MA, Pidala J, Kumar A, Terasawa T, Djulbegovic B. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone marrow transplantation. 47(9) : 1164-70, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22562081
  • Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, Holcomb JB, Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, Weinstein R, Swinton McLaughlin LG, Djulbegovic B. Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB. Annals of internal medicine. 157(1) : 49-58, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22454395
  • Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A. Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. Journal of clinical epidemiology. 65(6) : 602-9, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22424985
  • Gil-Herrera E, Yalcin A, Tsalatsanis A, Barnes LE, Djulbegovic B. Towards a classification model to identify hospice candidates in terminally ill patients. Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference. 2012: 1278-81, 2012. http://www.ncbi.nlm.nih.gov/pubmed/23366132
  • Miladinovic B, Kumar A, Mhaskar R, Kim S, Schonwetter R, Djulbegovic B. A flexible alternative to the Cox proportional hazards model for assessing the prognostic accuracy of hospice patient survival. PloS one. 7(10) : e47804, 2012. http://www.ncbi.nlm.nih.gov/pubmed/23082220
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. Journal of the National Comprehensive Cancer Network : JNCCN. 10(10) : 1211-9, 2012. http://www.ncbi.nlm.nih.gov/pubmed/23054875
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F. Multiple myeloma. Journal of the National Comprehensive Cancer Network : JNCCN. 9(10) : 1146-83, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21975914
  • Tsalatsanis A, Barnes LE, Hozo I, Djulbegovic B. Extensions to regret-based decision curve analysis: an application to hospice referral for terminal patients. BMC medical informatics and decision making. 11: 77, 2011. http://www.ncbi.nlm.nih.gov/pubmed/22196308
  • Tsalatsanis A, Gil-Herrera E, Yalcin A, Djulbegovic B, Barnes L. Designing patient-centric applications for chronic disease management. Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference. 2011: 3146-9, 2011. http://www.ncbi.nlm.nih.gov/pubmed/22255007
  • Gil-Herrera E, Yalcin A, Tsalatsanis A, Barnes LE, Djulbegovic B. Rough Set Theory based prognostication of life expectancy for terminally ill patients. Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference. 2011: 6438-41, 2011. http://www.ncbi.nlm.nih.gov/pubmed/22255812
  • Kumar A, Hozo I, Wheatley K, Djulbegovic B. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. American journal of hematology. 86(1) : 18-24, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21120867
  • Kumar A, Galeb S, Djulbegovic B. Treatment of patients with multiple myeloma: an overview of systematic reviews. Acta haematologica. 125(1-2) : 8-22, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21150183
  • Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ. Optimism bias leads to inconclusive results-an empirical study. Journal of clinical epidemiology. 64(6) : 583-93, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21163620
  • Djulbegovic M, Djulbegovic B. Implications of the principle of question propagation for comparative-effectiveness and "data mining" research. JAMA. 305(3) : 298-9, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21245185
  • Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, Norris SL, Williams JW, Atkins D, Meerpohl J, Schünemann HJ. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). Journal of clinical epidemiology. 64(4) : 407-15, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21247734
  • Dahm P, Djulbegovic B. The Australian 'FORM' approach to guideline development: the quest for the perfect system. BMC medical research methodology. 11: 17, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21324126
  • Tsalatsanis A, Barnes L, Hozo I, Skvoretz J, Djulbegovic B. A social network analysis of treatment discoveries in cancer. PloS one. 6(3) : e18060, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21464896
  • Miladinovic B, Kumar A, Hozo I, Djulbegovic B. Instrumental variable meta-analysis of individual patient data: application to adjust for treatment non-compliance. BMC medical research methodology. 11: 55, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21510899
  • Djulbegovic B, Paul A. From efficacy to effectiveness in the face of uncertainty: indication creep and prevention creep. JAMA. 305(19) : 2005-6, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21586716
  • Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, Alonso-Coello P, Djulbegovic B, Atkins D, Falck-Ytter Y, Williams JW, Meerpohl J, Norris SL, Akl EA, Schünemann HJ. GRADE guidelines: 5. Rating the quality of evidence--publication bias. Journal of clinical epidemiology. 64(12) : 1277-82, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21802904
  • Djulbegovic B. Uncertainty and equipoise: at interplay between epistemology, decision making and ethics. The American journal of the medical sciences. 342(4) : 282-9, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21817885
  • Pidala J, Djulbegovic B, Anasetti C, Kharfan-Dabaja M, Kumar A. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. The Cochrane database of systematic reviews. (10) : CD008818, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21975786
  • Schroen AT, Petroni GR, Wang H, Thielen MJ, Sargent D, Benedetti JK, Cronin WM, Wickerham DL, Wang XF, Gray R, Cohn WF, Slingluff CL, Djulbegovic B. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clinical trials (London, England). 8(5) : 591-600, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21878447
  • Kumar A, List AF, Hozo I, Komrokji R, Djulbegovic B. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica. 95(2) : 340-2; author reply 343-4, 2010. http://www.ncbi.nlm.nih.gov/pubmed/19850902
  • Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma. The Cochrane database of systematic reviews. (3) : CD003188, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20238320
  • Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schünemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 303(12) : 1180-7, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20332404
  • Roback JD, Caldwell S, Carson J, Davenport R, Drew MJ, Eder A, Fung M, Hamilton M, Hess JR, Luban N, Perkins JG, Sachais BS, Shander A, Silverman T, Snyder E, Tormey C, Waters J, Djulbegovic B. Evidence-based practice guidelines for plasma transfusion. Transfusion. 50(6) : 1227-39, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20345562
  • Mhaskar AR, Quinn G, Vadaparampil S, Djulbegovic B, Gwede CK, Kumar A. Timing of first-line cancer treatments - early versus late - a systematic review of phase III randomized trials. Cancer treatment reviews. 36(8) : 621-8, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20444550
  • Herold CI, Djulbegovic B, Hozo I, Lyman GH. Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. Breast cancer research and treatment. 121(3) : 771-6, 2010. http://www.ncbi.nlm.nih.gov/pubmed/19806449
  • Schroen AT, Petroni GR, Wang H, Gray R, Wang XF, Cronin W, Sargent DJ, Benedetti J, Wickerham DL, Djulbegovic B, Slingluff CL. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clinical trials (London, England). 7(4) : 312-21, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20595245
  • Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ (Clinical research ed.). 341: c4543, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20843937
  • Tsalatsanis A, Hozo I, Vickers A, Djulbegovic B. A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-making. BMC medical informatics and decision making. 10: 51, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20846413
  • Wager E, Mhaskar R, Warburton S, Djulbegovic B. JAMA published fewer industry-funded studies after introducing a requirement for independent statistical analysis. PloS one. 5(10) : e13591, 2010. http://www.ncbi.nlm.nih.gov/pubmed/21042585
  • Djulbegovic B. Management of venous Thromboembolism in cancer: a brief review of risk-benefit approaches and guidelines' recommendations. The journal of supportive oncology. 8(2) : 84-91, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20464888
  • Charlton BG. The Zombie science of evidence-based medicine: a personal retrospective. A commentary on Djulbegovic, B., Guyatt, G. H. & Ashcroft, R. E. (2009). Cancer Control, 16, 158-168. Journal of evaluation in clinical practice. 15(6) : 930-4, 2009. http://www.ncbi.nlm.nih.gov/pubmed/20367686
  • Miles A. Evidence-based medicine: requiescat in pace? A commentary on Djulbegovic, B., Guyatt, G. H. & Ashcroft, R. E. (2009) Cancer Control, 16, 158-168. Journal of evaluation in clinical practice. 15(6) : 924-9, 2009. http://www.ncbi.nlm.nih.gov/pubmed/20367685
  • Sturmberg JP. EBM: a narrow and obsessive methodology that fails to meet the knowledge needs of a complex adaptive clinical world: a commentary on Djulbegovic, B., Guyatt, G. H. & Ashcroft, R. E. (2009) Cancer Control, 16, 158-168. Journal of evaluation in clinical practice. 15(6) : 917-23, 2009. http://www.ncbi.nlm.nih.gov/pubmed/20367684
  • Tanenbaum SJ. More of the same: a commentary on Djulbegovic, B., Guyatt, G. H. & Ashcroft, R. E. (2009) Cancer Control, 16, 158-168. Journal of evaluation in clinical practice. 15(6) : 915-6, 2009. http://www.ncbi.nlm.nih.gov/pubmed/20367683
  • Loughlin M. The search for substance: a quest for the identity-conditions of evidence-based medicine and some comments on Djulbegovic, B., Guyatt, G. H. & Ashcroft, R. E. (2009) Cancer Control, 16, 158-168. Journal of evaluation in clinical practice. 15(6) : 910-4, 2009. http://www.ncbi.nlm.nih.gov/pubmed/20367682
  • Tonelli MR. A late and shifting foundation: a commentary on Djulbegovic, B., Guyatt, G. H. & Ashcroft, R. E. (2009) Cancer Control, 16, 158-168. Journal of evaluation in clinical practice. 15(6) : 907-9, 2009. http://www.ncbi.nlm.nih.gov/pubmed/20367681
  • Silva SA, Wyer PC. Where is the wisdom? II - Evidence-based medicine and the epistemological crisis in clinical medicine. Exposition and commentary on Djulbegovic, B., Guyatt, G. H. & Ashcroft, R. E. (2009) Cancer Control, 16, 158-168. Journal of evaluation in clinical practice. 15(6) : 899-906, 2009. http://www.ncbi.nlm.nih.gov/pubmed/20367680
  • Dekay ML. Physicians' anticipated regret and diagnostic testing: comment on Hozo and Djulbegovic, 2008. Medical decision making : an international journal of the Society for Medical Decision Making. 29(3) : 317-9; author reply 320-4, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19506085
  • Freedman A, Neelapu S, Nichols C, Robertson M, Djulbegovic B, et.al. A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T and GM-CSF Following Rituximab in Patients with Follicular Lymphoma. J Clin Oncol. : In Press, 2009.
  • Djulbegovic B, Guyatt G, Ashcroft R. Epistemological Inquiries in Evidence Based Medicine. Cancer Control. : In Press, 2009.
  • Djulbegovic B. The paradox of equipoise: the principle that drives and limits therapeutic discoveries in clinical research. Cancer control : journal of the Moffitt Cancer Center. 16(4) : 342-7, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19910921
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F. NCCN clinical practice guidelines in oncology: multiple myeloma. Journal of the National Comprehensive Cancer Network : JNCCN. 7(9) : 908-42, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19878637
  • Pidala J, Anasetti C, Kharfan-Dabaja MA, Cutler C, Sheldon A, Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(11) : 1415-21, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19822301
  • Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(9) : 1005-13, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19660713
  • Djulbegovic B, Trikalinos TA, Roback J, Chen R, Guyatt G. Impact of quality of evidence on the strength of recommendations: an empirical study. BMC health services research. 9: 120, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19622148
  • Mhaskar R, Kumar A, Behera M, Kharfan-Dabaja MA, Djulbegovic B. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(8) : 893-902, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19589478
  • Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. The Cochrane database of systematic reviews. (3) : CD007303, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19588423
  • Briel M, Lane M, Montori VM, Bassler D, Glasziou P, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Culebro CR, da Silva SA, Flynn DN, Elamin MB, Strahm B, Murad MH, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Abu Elnour NO, You JJ, Karanicolas PJ, Bucher HC, Lampropulos JF, Nordmann AJ, Burns KE, Mulla SM, Raatz H, Sood A, Kaur J, Bankhead CR, Mullan RJ, Nerenberg KA, Vandvik PO, Coto-Yglesias F, Schünemann H, Tuche F, Chrispim PP, Cook DJ, Lutz K, Ribic CM, Vale N, Erwin PJ, Perera R, Zhou Q, Heels-Ansdell D, Ramsay T, Walter SD, Guyatt GH. Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). Trials. 10: 49, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19580665
  • Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 301(22) : 2349-61, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19509382
  • Dorr DA, Burdon R, West DP, Lagman J, Georgopoulos C, Belknap SM, McKoy JM, Djulbegovic B, Edwards BJ, Weitzman SA, Boyle S, Tallman MS, Talpaz M, Sartor O, Bennett CL. Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(11) : 3850-5, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19458059
  • Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(18) : 3036-43, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19414675
  • Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet (London, England). 373(9674) : 1532-42, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19410717
  • Djulbegovic B, Guyatt GH, Ashcroft RE. Epistemologic inquiries in evidence-based medicine. Cancer control : journal of the Moffitt Cancer Center. 16(2) : 158-68, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19337202
  • Djulbegovic B. Risk prediction versus diagnosis: preserving clinical nuance in a binary world. Annals of internal medicine. 150(3) : 223; author reply 224, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19189922
  • Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. Journal of the National Cancer Institute. 101(2) : 100-6, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19141779
  • Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Nasta S, O'Connor OA, Shi H, Boral AL, Fisher RI. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Annals of oncology : official journal of the European Society for Medical Oncology. 20(3) : 520-5, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19074748
  • Jaeschke R, Guyatt GH, Dellinger P, Schünemann H, Levy MM, Kunz R, Norris S, Bion J. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ (Clinical research ed.). 337: a744, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18669566
  • Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 111(1) : 25-41, 2008. http://www.ncbi.nlm.nih.gov/pubmed/17954703
  • Schünemann HJ, Schünemann AH, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, Williams JW, Kunz R, Craig J, Montori VM, Bossuyt P, Guyatt GH. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ (Clinical research ed.). 336(7653) : 1106-10, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18483053
  • Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schünemann HJ. Going from evidence to recommendations. BMJ (Clinical research ed.). 336(7652) : 1049-51, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18467413
  • Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ (Clinical research ed.). 336(7651) : 995-8, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18456631
  • Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed.). 336(7650) : 924-6, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18436948
  • Djulbegovic B, Kumar A, , Bepler G, Clarke M, Soares HP, Hozo I, Bennett CL. Treatment success in cancer-reply. Arch Intern Med. 168: 2173-2174, 2008.
  • Rizzo JD, Somerfield MR, Hagerty KL,Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode M, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. American Society of Clinical Oncology/American Society Of Hematology 2007 Clinical Practice Guideline Update on the Use of Epoetin And Darbepoetin. J Clin Oncol. 26: 132-149, 2008.
  • Hoppe RT, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hudson MM, Kaminski MS, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD. Hodgkin disease/lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 6(6) : 594-622, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18597713
  • Rodgers GM, Becker PS, Bennett CL, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Djulbegovic B, Garst JL, Gilreath JA, Kraut EH, Lin WC, Matulonis U, Millenson M, Reinke D, Rosenthal J, Sabbatini P, Schwartz RN, Stein RS, Vij R. Cancer- and chemotherapy-induced anemia. Journal of the National Comprehensive Cancer Network : JNCCN. 6(6) : 536-64, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18597709
  • Kunz R, Djulbegovic B, Schunemann HJ, Stanulla M, Muti P, Guyatt G. Misconceptions, challenges, uncertainty, and progress in guideline recommendations. Seminars in hematology. 45(3) : 167-75, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18582623
  • Hozo I, Schell MJ, Djulbegovic B. Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach. Seminars in hematology. 45(3) : 150-9, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18582621
  • Djulbegovic B, Kumar A. Multiple myeloma: detecting the effects of new treatments. Lancet (London, England). 371(9625) : 1642-4, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18486726
  • Hozo I, Djulbegovic B. When is diagnostic testing inappropriate or irrational? Acceptable regret approach. Medical decision making : an international journal of the Society for Medical Decision Making. 28(4) : 540-53, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18480041
  • Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL. Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Archives of internal medicine. 168(6) : 632-42, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18362256
  • Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 299(8) : 914-24, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18314434
  • Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF. Recommendations on the use of 18F-FDG PET in oncology. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 49(3) : 480-508, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18287273
  • Djulbegovic B. Evidence-Based Medicine: In Its Place. Medical decision making : an international journal of the Society for Medical Decision Making. , 2008. http://www.ncbi.nlm.nih.gov/pubmed/18270305
  • Wilcox RA, Djulbegovic B, Moffitt HL, Guyatt GH, Montori VM. Randomized trials in oncology stopped early for benefit. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(1) : 18-9, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18165635
  • Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(1) : 132-49, 2008. http://www.ncbi.nlm.nih.gov/pubmed/17954713
  • Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Liberati A, Vist GE, Schünemann HJ. Incorporating considerations of resources use into grading recommendations. BMJ (Clinical research ed.). 336(7654) : 1170-3, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18497416
  • Tanvetyanon T, Soares HP, Djulbegovic B, Jacobsen PB, Bepler G. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2(12) : 1091-7, 2007. http://www.ncbi.nlm.nih.gov/pubmed/18090580
  • Djulbegovic B, Hozo I, Lyman GH. Estimating net benefits and harms of screening mammography in women age 40 to 49 years. Annals of internal medicine. 147(12) : 882, 2007. http://www.ncbi.nlm.nih.gov/pubmed/18087062
  • Kharfan-Dabaja MA, Kumar A, Behera M, Djulbegovic B. Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence? British journal of haematology. 139(2) : 234-42, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17897299
  • Djulbegovic B, Angelotta C, Knox KE, Bennett CL. The sound and the fury: financial conflicts of interest in oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(24) : 3567-9, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17704401
  • Bennett CL, Nebeker JR, Yarnold PR, Tigue CC, Dorr DA, McKoy JM, Edwards BJ, Hurdle JF, West DP, Lau DT, Angelotta C, Weitzman SA, Belknap SM, Djulbegovic B, Tallman MS, Kuzel TM, Benson AB, Evens A, Trifilio SM, Courtney DM, Raisch DW. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Archives of internal medicine. 167(10) : 1041-9, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17533207
  • Djulbegovic B. Articulating and responding to uncertainties in clinical research. The Journal of medicine and philosophy. 32(2) : 79-98, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17454416
  • Soares HP, Kumar A, Djulbegovic B. Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence. Cancer treatment reviews. 33(1) : 87-9, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17081695
  • Kumar A, Soares HP, Balducci L, Djulbegovic B. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(10) : 1272-6, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17401017
  • Behera M, Kumar A, Soares HP, Sokol L, Djulbegovic B. Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer control : journal of the Moffitt Cancer Center. 14(2) : 160-6, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17387301
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yahalom J, Yunus F. Multiple myeloma. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 5(2) : 118-47, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17335683
  • Djulbegovic B, Hozo I. When should potentially false research findings be considered acceptable? PLoS medicine. 4(2) : e26, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17326703
  • Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, Richardson PG, Anderson KC, Soiffer RJ, Alyea EP. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 13(2) : 183-96, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17241924
  • Scheetz MH, McKoy JM, Parada JP, Djulbegovic B, Raisch DW, Yarnold PR, Zagory J, Trifilio S, Jakiche R, Palella F, Kahn A, Chandler K, Bennett CL. Systematic review of piperacillin-induced neutropenia. Drug safety. 30(4) : 295-306, 2007. http://www.ncbi.nlm.nih.gov/pubmed/17408306
  • Djulbegovic B. Evidence and decision making. Commentary on M.R. Tonelli (2006), Integrating evidence into clinical practice: an alternative approach to evidence-based approaches. Journal of Evaluation in Clinical Practice 12, 248-256. Journal of evaluation in clinical practice. 12(3) : 257-9, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16722903
  • Glasziou P, Djulbegovic B, Burls A. Are systematic reviews more cost-effective than randomised trials? Lancet (London, England). 367(9528) : 2057-8, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16798380
  • Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute. 98(10) : 708-14, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16705125
  • Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 3 November to 24 November, 2005: a summary. Cancer treatment reviews. 32(3) : 239-41, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16624491
  • Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 25 August to 27 October 2005: A summary. Cancer treatment reviews. 32(2) : 149-55, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16520003
  • Prentice AG, Glasmacher A, Djulbegovic B. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy. British journal of haematology. 132(5) : 656-8; author reply 658-9, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16445845
  • Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 16 June to 18 August 2005: a summary. Cancer treatment reviews. 32(1) : 59-64, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16434143
  • Hoppe RT. Advani RH. Bierman PJ. Bloomfield CD. Buadi F, Djulbegovic B. Forero A. Gordon LI. Hernandez-Ilizaliturri FJ. Kaminski MS. Love G. Maloney DG. Mauch PM. Moore JO. Schilder RJ. Weiss L. Winter JN. Yahalom J. Zelenetz AD. Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network.. 3: 210-230, 2006.
  • Stem Cell Trialists Group (Principal Investigator: Djulbegovic B). Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs. bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplant. 38: 539-546, 2006.
  • Djulbegovic B, Lyman GH. Screening mammography at 40-49 years: regret or no regret? Lancet (London, England). 368(9552) : 2035-7, 2006. http://www.ncbi.nlm.nih.gov/pubmed/17161713
  • Soares HP, Kumar A, Djulbegovic B. Evidence profiles for lung cancer: benefit/harms data based on the totality of randomized evidence. Cancer treatment reviews. 32(8) : 652-5, 2006. http://www.ncbi.nlm.nih.gov/pubmed/17008011
  • Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(30) : 4867-74, 2006. http://www.ncbi.nlm.nih.gov/pubmed/17001068
  • Kumar A, Djulbegovic B. Myeloma (multiple). Clinical evidence. (15) : 1-29, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16973003
  • Kumar A, Soares HP, Djulbegovic B. Evidence profiles for colo-rectal cancer: benefit/harms data based on the totality of randomized evidence. Cancer treatment reviews. 32(7) : 577-80, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16919883
  • Djulbegovic B, Soares HP, Kumar A. What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. Cancer treatment reviews. 32(7) : 572-6, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16914268
  • Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Benett CL, Langensiepen S, Hyde C, Engert E. Erythropoietin or darbepoetin for patients with cancer. The Cochrane database of systematic reviews. (3) : CD003407, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16856007
  • Pavlidis N, Stahel R, Clarke M, Djulbegovic B. Cancer treatment reviews welcomes submission of the Cochrane Reviews. Cancer treatment reviews. 32(4) : 243-4, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16713102
  • Rodgers GM, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Demetri GD, Djulbegovic B, Garst JL, Gore M, Kraut EH, Lin WC, Millenson M, Mock V, Reinke D, Rosenthal J, Sabbatini P. Cancer- and treatment-related anemia. Journal of the National Comprehensive Cancer Network : JNCCN. 3(6) : 772-89, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16316613
  • Stem cell Trialists Collaborative Group (PI: Djulbegovic B). Allogeneic Peripheral Blood Stem Cell Versus Bone Marrow Transplantation in the Management of Hematological Malignancies: An Individual Patient Data Meta-Analysis of 9 Randomized Trials and 1,111 Patients. J Clin Oncol. 23: 5074-5087, 2005.
  • Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 19 May to 9 June 2005: a summary. Cancer treatment reviews. 31(8) : 653-6, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16298072
  • Bickerdike L, Djulbegovic B. High-quality evidence in oncology from 14 April to 12 May 2005: a summary. Cancer treatment reviews. 31(7) : 587-9, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16243438
  • Lyman GH, Djulbegovic B. The challenge of systematic reviews of diagnostic and staging studies in cancer. Cancer treatment reviews. 31(8) : 628-39, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16225994
  • Djulbegovic B, Frohlich A, Bennett CL. Acting on imperfect evidence: How much regret are we ready to accept? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(28) : 6822-5, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16145058
  • Vincent S, Djulbegovic B. Oncology treatment recommendations can be supported only by 1-2% of high-quality published evidence. Cancer treatment reviews. 31(4) : 319-22, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16006047
  • Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(18) : 4198-214, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15961767
  • Hozo I, Djulbegovic B, Clark O, Lyman GH. Use of re-randomized data in meta-analysis. BMC medical research methodology. 5: 17, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15882470
  • Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 1st September to 14th October 2004: a summary. Cancer treatment reviews. 31(2) : 155-7, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15847985
  • Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC medical research methodology. 5: 13, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15840177
  • Djulbegovic B. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines. Best practice & research. Clinical haematology. 18(3) : 455-66, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15792920
  • Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B. Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA. 293(8) : 970-8, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15728168
  • Djulbegovic B, Bickerdike L. High-quality evidence in oncology from 22nd June to 26th August 2004: a summary. Cancer treatment reviews. 31(1) : 63-7, 2005. http://www.ncbi.nlm.nih.gov/pubmed/15707707
  • Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, Reaman G, Chalmers I, Djulbegovic B. Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ (Clinical research ed.). 331(7528) : 1295, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16299015
  • Djulbegovic B. Where is the evidence? European journal of cancer (Oxford, England : 1990). 40(18) : 2637, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15648121
  • Djulbegovic B. Lifting the fog of uncertainty from the practice of medicine. BMJ (Clinical research ed.). 329(7480) : 1419-20, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15604164
  • Djulbegovic B, Vincent S. High-quality evidence in oncology from 18th May to 15th June 2004: a summary. Cancer treatment reviews. 30(8) : 721-3, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15541583
  • Djulbegovic B, Vincent S. High-quality evidence in oncology from 20th April to 11th May 2004: a summary. Cancer treatment reviews. 30(7) : 665-7, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15531400
  • Djulbegovic B. Well informed uncertainties about the effects of treatment: paradox exists in dealing with uncertainty. BMJ (Clinical research ed.). 328(7446) : 1018, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15105342
  • Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 103(9) : 3271-7, 2004. http://www.ncbi.nlm.nih.gov/pubmed/14726402
  • Soares HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, Djulbegovic B. Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ (Clinical research ed.). 328(7430) : 22-4, 2004. http://www.ncbi.nlm.nih.gov/pubmed/14703540
  • Mann H, Djulbegovic B. Biases due to differences in the treatments selected for comparison (comparator bias). James Lind Library. www.jameslindlibrary.org, 2004.
  • Djulbegovic B. Commentary on "Perceptions of equipoise are crucial to trial participation". Cochrane Collaboration Method Groups Newsletter. 8: 19-20, 2004.
  • Djulbegovic B, Seidenfeld J, Bonnel C, Kumar A. Nonmyeloablative allogeneic stem cell transplantation for hematologic malignancies: a systematic review. Cancer Control. 10: 17-41, 2003.
  • Mann H, Djulbegovic B, Gold P. Failure of equipoise to resolve the ethical tension in a randomized clinical trial. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics. 31(1) : 5-6, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12762098
  • He Y, Wheatley K, Clark O, Glasmacher A, Ross H, Djulbegovic B. Early versus deferred treatment for early stage multiple myeloma. The Cochrane database of systematic reviews. (1) : CD004023, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12535504
  • Djulbegovic B, Seidenfeld J, Bonnell C, Kumar A. Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review. Cancer control : journal of the Moffitt Cancer Center. 10(1) : 17-41, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12598853
  • Djulbegovic B, Coleman R, Stahel R, Singh D, Lyman G. Evidence-based oncology in cancer treatment reviews. Cancer treatment reviews. 29(1) : 45-50, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12633579
  • Djulbegovic B, Singh D. Evidence-based oncology section - aims and scope. Cancer treatment reviews. 29(1) : 51-3, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12633580
  • Singh D, Djulbegovic B. Evidence-based Oncology section--policies and scope. Cancer treatment reviews. 29(2) : 121-2, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12670454
  • Mann H, Djulbegovic B. Off-study availability of investigational treatments. Lancet (London, England). 361(9365) : 1302, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12699986
  • Mann H, Djulbegovic B. Choosing a control intervention for a randomised clinical trial. BMC medical research methodology. 3: 7, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12709266
  • Kumar A, Loughran T, Alsina M, Durie BG, Djulbegovic B. Management of multiple myeloma: a systematic review and critical appraisal of published studies. The Lancet. Oncology. 4(5) : 293-304, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12732167
  • Djulbegovic B, Cantor A, Clarke M. The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials. Accountability in research. 10(4) : 301-15, 2003. http://www.ncbi.nlm.nih.gov/pubmed/14989285
  • Mann H, Djulbegovic B. Clinical equipoise and the therapeutic misconception. The Hastings Center report. 33(5) : 4; author reply 4-5, 2003. http://www.ncbi.nlm.nih.gov/pubmed/14696270
  • Glasmacher A, Prentice A, Gorschlüter M, Engelhart S, Hahn C, Djulbegovic B, Schmidt-Wolf IG. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 21(24) : 4615-26, 2003. http://www.ncbi.nlm.nih.gov/pubmed/14673051
  • Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The hematology journal : the official journal of the European Haematology Association. 4(6) : 379-98, 2003. http://www.ncbi.nlm.nih.gov/pubmed/14671610
  • Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschlüter M, Ziske C, Schmidt-Wolf IG. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica. 88(11) : 1304-15, 2003. http://www.ncbi.nlm.nih.gov/pubmed/14607760
  • Clark OA, Lyman G, Castro AA, Clark LG, Djulbegovic B. Colony stimulating factors for chemotherapy induced febrile neutropenia. The Cochrane database of systematic reviews. (3) : CD003039, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12917942
  • Bepler G, Goodridge Carney D, Djulbegovic B, Clark RA, Tockman M. A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest. Cancer control : journal of the Moffitt Cancer Center. 10(4) : 306-14, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12915809
  • Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ (Clinical research ed.). 326(7400) : 1167-70, 2003. http://www.ncbi.nlm.nih.gov/pubmed/12775614
  • The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 121: 749-757, 2003.
  • Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 100(7) : 2303-20, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12239138
  • Djulbegovic B. Denominator problem needs to be addressed. BMJ. 325: 1420, 2002.
  • Clark O, Clark L, Cutler C, Wheatley K, Djulbegovic B. Allogeneic peripheral blood stem cells vs. bone marrow transplant for hematological malignancies (Protocol for the Cochrane Review). In: The Cochrane Library. (4) , 2002.
  • Adams JR, Lyman GH, Djubegovic B, Feinglass J, Bennett CL. G-CSF as prophylaxis of febrile neutropenia in SCLC. Expert Opin Pharmacother.. 3: 1273-81, 2002.
  • Cruse H, Winiarek M, Marshburn J, Clark O, Djulbegovic B. Quality and methods of developing practice guidelines. BMC health services research. 2: 1, 2002. http://www.ncbi.nlm.nih.gov/pubmed/11825346
  • Bottomley A, Thomas R, van Steen K, Flechtner H, Djulbegovic B. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? The Lancet. Oncology. 3(3) : 145-53, 2002. http://www.ncbi.nlm.nih.gov/pubmed/11902500
  • Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. The American journal of medicine. 112(5) : 406-11, 2002. http://www.ncbi.nlm.nih.gov/pubmed/11904116
  • Wheatley K, Djulbegovic B, Glasmacher A. Priority-setting decisions for new cancer drugs. Lancet (London, England). 359(9316) : 1525, 2002. http://www.ncbi.nlm.nih.gov/pubmed/11988282
  • Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A. Bisphosphonates in multiple myeloma. The Cochrane database of systematic reviews. (3) : CD003188, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12137679
  • Djulbegovic B, Hozo I. At what degree of belief in a research hypothesis is a trial in humans justified? Journal of evaluation in clinical practice. 8(2) : 269-76, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12180373
  • Bottomley A, Thomas R, Van Steen K, Flechtner H, Djulbegovic B. Erythropoietin improves quality of life--a response. The Lancet. Oncology. 3(9) : 527, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12217788
  • Clark O, Adams JR, Bennett CL, Djulbegovic B. Erythropoietin, uncertainty principle and cancer related anaemia. BMC cancer. 2: 23, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12270068
  • Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(19) : 4083-107, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12351606
  • Djulbegovic B. Association between competing interests and conclusions. Denominator problem needs to be addressed. BMJ (Clinical research ed.). 325(7377) : 1420; author reply 1420, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12480865
  • Kumar A, Djulbegovic B. Why evidence based oncology management. The Journal of oncology management : the official journal of the American College of Oncology Administrators. 11(6) : 13-6, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12502287
  • Lyman GH, Djulbegovic B. Understanding economic analyses. Evidence-based Oncology. 2: 2-5, 2001.
  • Djulbegovic B, Clarke M. Informing patients about uncertainty in clinical trials. JAMA. 285: 2713-2714, 2001.
  • Lilford RJ, Djulbegovic B. Declaration of Helsinki should be strengthened. Equipoise is essential principle of human experimentation. BMJ (Clinical research ed.). 322(7281) : 299-300, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11157551
  • Djulbegovic B, Clarke M. Scientific and ethical issues in equivalence trials. JAMA. 285(9) : 1206-8, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11231752
  • Djulbegovic B. Commentary on "Clinical score for cancer patients with febrile neutropenia. ACP J Club. 134: 76, 2001.
  • Djulbegovic B. Placebo-controlled trials. Ann Intern Med. 135: 62-63, 2001.
  • Djulbegovic B. Placebo-controlled trials. Annals of internal medicine. 135(1) : 62-4, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11434740
  • Djulbegovic B. Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research. Current oncology reports. 3(5) : 389-95, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11489238
  • Djulbegovic B, Clarke M. Ethical issues in the reporting of clinical trials. JAMA. 286(13) : 1577-8, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11585477
  • Djulbegovic B, Cohen Y. The natural history of refractory idiopathic thrombocytopenic purpura. Blood. 98(7) : 2282-3, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11592263
  • Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A. Bisphosphonates in multiple myeloma. The Cochrane database of systematic reviews. (4) : CD003188, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11687178
  • Clark O, Clark L, Djulbegovic B. Is clinical research still too haphazard? Lancet (London, England). 358(9293) : 1648, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11716926
  • Djulbegovic B, Adams JR, Lyman GH, Lacevic M, Hozo I, Greenwich M, Bennett CL. Evaluation and appraisal of randomized controlled trials in myeloma. Annals of oncology : official journal of the European Society for Medical Oncology. 12(11) : 1611-7, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11822763
  • Lilford RJ, Djulbegovic B. Uncertainty about clinical equipoise. Equipose and uncertainty principle are not mutually exclusive. BMJ (Clinical research ed.). 322(7289) : 795, 2001. http://www.ncbi.nlm.nih.gov/pubmed/11322146
  • Djulbegovic B. Commentary to the CONSORT Statement: revised recommendations for improving the quality of reports of parallel group randomized trials. Cochrane Collaboration Methods Groups Newsletter. 5: 11-12, 2001.
  • Kantardzic M, Hamdan H, Djulbegovic B. Artificial Neural Networks Approach in Diagnostics of Polycythemia Vera. Internat J Computers and Their Applications.. 8: 74-79, 2001.
  • Djulbegovic B. Thalidomide is active drug against myeloma that failed transplant. In: Evidence-based Oncology. 1: 16-17, 2000.
  • Djulbegovic B, Lyman GH, Ruckdeschel J. Why Evidence-based Oncology. Evidence-based Oncology. , 2000.
  • Djulbegovic B, Morris L, Lyman GH. Evidentiary challenges to evidence-based medicine. Journal of evaluation in clinical practice. 6(2) : 99-109, 2000. http://www.ncbi.nlm.nih.gov/pubmed/10970004
  • Djulbegovic B, Hozo I, Lyman GH. Linking evidence-based medicine therapeutic summary measures to clinical decision analysis. MedGenMed : Medscape general medicine. 2(1) : E6, 2000. http://www.ncbi.nlm.nih.gov/pubmed/11104452
  • Knox KS, Adams JR, Djulbegovic B, Stinson TJ, Tomor C, Bennet CL. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. Annals of oncology : official journal of the European Society for Medical Oncology. 11(12) : 1591-5, 2000. http://www.ncbi.nlm.nih.gov/pubmed/11205468
  • Lilford RJ, Djulbegovic B. Equipoise is essential principle of human experimentation. BMJ. 322: 299-300, 2000.
  • Djulbegovic B, Lyman GH, Hozo I. Talking about treatment. Annals of internal medicine. 132(1) : 94, 2000. http://www.ncbi.nlm.nih.gov/pubmed/10627263
  • Knox KS, Adams JR, Djulbegovic B, Stinson TJ, Bennett CL. Quality and Dissemination of Industry Sponsored Economic Analyses of Six Novel Drugs Used in Oncology. Ann Oncology. 11: 1591-1595, 2000.
  • Djulbegovic B, Bennett CL, Adams JR, Lyman GH. Industry-sponsored research. Lancet. 356: 2194, 2000.
  • Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Archives of internal medicine. 160(11) : 1630-8, 2000. http://www.ncbi.nlm.nih.gov/pubmed/10847256
  • Djulbegovic B. Acquired anaemias and polycythaemia. Lancet (London, England). 356(9229) : 596, 2000. http://www.ncbi.nlm.nih.gov/pubmed/10950261
  • Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH. The uncertainty principle and industry-sponsored research. Lancet (London, England). 356(9230) : 635-8, 2000. http://www.ncbi.nlm.nih.gov/pubmed/10968436
  • Djulbegovic B, Cantor A, Lyman GH, Ruckdeschel JC. Understanding treatment benefits and harms. Evidence-based Oncology. 1: 66-68, 2000.
  • Hozo I, Djulbegovic B. Calculating confidence intervals for threshold and post-test probabilities. M.D. computing : computers in medical practice. 15(2) : 110-5, 1999. http://www.ncbi.nlm.nih.gov/pubmed/9540324
  • Djulbegovic B, Hozo I. Computer program for the diagnosis and treatment of polycythemia rubra vera. M.D. computing : computers in medical practice. 16(1) : 83-9, 1999. http://www.ncbi.nlm.nih.gov/pubmed/10202430
  • Djulbegovic B, Loughran TP, Hornung CA, Kloecker G, Efthimiadis EN, Hadley TJ, Englert J, Hoskins M, Goldsmith GH. The quality of medical evidence in hematology-oncology. The American journal of medicine. 106(2) : 198-205, 1999. http://www.ncbi.nlm.nih.gov/pubmed/10230750
  • Hozo I, Djulbegovic B. Using the Internet to calculate clinical action thresholds. Computers and biomedical research, an international journal. 32(2) : 168-85, 1999. http://www.ncbi.nlm.nih.gov/pubmed/10337498
  • Djulbegovic B, Hozo I, Schwartz A, McMasters KM. Acceptable regret in medical decision making. Medical hypotheses. 53(3) : 253-9, 1999. http://www.ncbi.nlm.nih.gov/pubmed/10580533
  • Djulbegovic B, Hendler FJ, Pavletic S. Reasoning by Identifying Goals of Treatment. Cancer control : journal of the Moffitt Cancer Center. 6(4) : 377-384, 1999. http://www.ncbi.nlm.nih.gov/pubmed/10758570
  • Djulbegovic B. Two systematic reviews-two different answers. BMJ. , 1999.
  • Djulbegovic B, Hozo I, Fields KK, Sullivan D. High-Dose Chemotherapy in the Adjuvant Treatment of Breast Cancer: Benefit/Risk Analysis. Cancer control : journal of the Moffitt Cancer Center. 5(5) : 394-405, 1998. http://www.ncbi.nlm.nih.gov/pubmed/10761089
  • Djulbegovic B, Hadley T. Evaluating the quality of clinical guidelines. Linking decisions to medical evidence. Oncology (Williston Park, N.Y.). 12(11A) : 310-4, 1998. http://www.ncbi.nlm.nih.gov/pubmed/10028514
  • Djulbegovic B and Hozo I. Acting on evidence can only be done within the context of decision analysis. BMJ. , 1998.
  • Djulbegovic B. The Chief Knowledge Officer vs. Improvement in Science of Information Dissemination? BMJ. , 1998.
  • Djulbegovic B, Goldsmith G, Vaughn D, Birkimer J, Marasa M, Joseph G, Huang A, Hadley T. Comparison of the quality of life between HIV-positive haemophilia patients and HIV-negative haemophilia patients. Haemophilia : the official journal of the World Federation of Hemophilia. 2(3) : 166-72, 1996. http://www.ncbi.nlm.nih.gov/pubmed/27214111
  • Djulbegovic B, Marasa M, Pesto A, Kushner GM, Hadley T, Joseph G, Goldsmith G. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. American journal of hematology. 51(2) : 168-70, 1996. http://www.ncbi.nlm.nih.gov/pubmed/8579061
  • Djulbegovic B, Desoky AH. Equation and nomogram for calculation of testing and treatment thresholds. Medical decision making : an international journal of the Society for Medical Decision Making. 16(2) : 198-9, 1996. http://www.ncbi.nlm.nih.gov/pubmed/8778540
  • Djulbegovic B, Goldsmith G, Vaughn D, Birkimer J, Marasa M, Joseph G, Huang A, and Hadley T. Comparison of the quality of life between HIV positive hemophilia patients and HIV negative hemophilia patients. Haemophilia. 2: 166-172, 1996.
  • Djulbegovic B, Hozo I, Abdomerovic I, Hozo S. Diagnostic entropy as a function of therapeutic benefit/risk ratio. Medical hypotheses. 45(5) : 503-9, 1995. http://www.ncbi.nlm.nih.gov/pubmed/8748096
  • Djulbegovic B, Hannan MM, Bergman GE. Concomitant treatment with factor IX concentrates and antifibrinolytics in hemophilia B. Acta haematologica. 94 Suppl 1: 43-7; discussion 48, 1995. http://www.ncbi.nlm.nih.gov/pubmed/7571994
  • Djulbegovic B, Goldsmith GH. Guidelines for management of hemophilia A and B. Blood. 85(2) : 598-9, 1995. http://www.ncbi.nlm.nih.gov/pubmed/7812015
  • Djulbegovic B. Lack of prophylactic anticoagulant therapy is not associated with clinical thrombotic complications in patients with hemophilia who undergo orthopedic surgical procedures. American journal of hematology. 50(3) : 229-30, 1995. http://www.ncbi.nlm.nih.gov/pubmed/7485094
  • Djulbegovic B. Clinical problem-solving: still hazy after all these years. The New England journal of medicine. 332(5) : 333, 1995. http://www.ncbi.nlm.nih.gov/pubmed/7816074
  • Joseph G, Smith KJ, Hadley TJ, Djulbegovic B, Troup GM, Oldfather J, Barker RL. HLA-DR53 protects against thrombotic thrombocytopenic purpura/adult hemolytic uremic syndrome. American journal of hematology. 47(3) : 189-93, 1994. http://www.ncbi.nlm.nih.gov/pubmed/7942782
  • Joseph G, Hadley T, Djulbegovic B, Hamm J, Seeger J, Blumenreich M, Woodcock T. High-dose chlorambucil and dexamethasone for relapsed non-Hodgkin's lymphomas. American journal of clinical oncology. 16(4) : 319-22, 1993. http://www.ncbi.nlm.nih.gov/pubmed/8328409
  • Djulbegovic B. An estimation of life expectancy: the method is a message. Medical decision making : an international journal of the Society for Medical Decision Making. 13(3) : 245-6, 1993. http://www.ncbi.nlm.nih.gov/pubmed/8412554
  • Djulbegovic B, Woodcock TM. Mathematical modeling or waiting decades for an empirical answer? Medical decision making : an international journal of the Society for Medical Decision Making. 12(1) : 77, 1992. http://www.ncbi.nlm.nih.gov/pubmed/1538636
  • Djulbegovic B, Hendler FJ, Hamm J, Hadley T, Woodcock TM. Residual mediastinal mass after treatment of Hodgkin's disease: a decision analysis. Medical hypotheses. 38(2) : 166-75, 1992. http://www.ncbi.nlm.nih.gov/pubmed/1528159
  • Djulbegovic B, Blumenreich M, Hadley T, Joseph G. Meta-analysis of chemotherapy in multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 10(8) : 1366-7, 1992. http://www.ncbi.nlm.nih.gov/pubmed/1386103
  • Djulbegovic B, Hadley T, Joseph G. A new algorithm for the diagnosis of polycythemia. American family physician. 44(1) : 113-20, 1991. http://www.ncbi.nlm.nih.gov/pubmed/2058526
  • Djulbegović B, Hadley T, Yen F. Occurrence of high-grade T-cell lymphoma in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: case report and review of the literature. American journal of hematology. 36(1) : 63-4, 1991. http://www.ncbi.nlm.nih.gov/pubmed/1984685
  • Djulbegovic B, Hollenberg J, Woodcock TM, Herzig R. Comparison of different treatment strategies for diffuse large-cell lymphomas: a decision analysis. Medical decision making : an international journal of the Society for Medical Decision Making. 11(1) : 1-8, 1991. http://www.ncbi.nlm.nih.gov/pubmed/1709713
  • Hadley T, Djulbegovic B. Disseminated intravascular coagulation after factor IX complex resolved using purified factor IX concentrate. Annals of internal medicine. 115(8) : 621-2, 1991. http://www.ncbi.nlm.nih.gov/pubmed/1892334
  • Pasic R, Djulbegovic B, Softic Dz, Wittliff JL. Steroid receptors and breast cancer. Med Pregl. 1-2: 48-51, 1991.
  • Pasic R, Djulbegovic B, Wittliff JL. Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand binding. Journal of clinical laboratory analysis. 4(6) : 430-6, 1990. http://www.ncbi.nlm.nih.gov/pubmed/2283562
  • Pasic R, Djulbegovic B, Wittliff JL. Influence of O.C.T. embedding compound on determinations of estrogen and progestin receptors in breast cancer. Clinical chemistry. 35(12) : 2317-9, 1989. http://www.ncbi.nlm.nih.gov/pubmed/2591050
  • Djulbegoviĉ B, Hadley T, Paŝiĉ R. A new algorithm for diagnosis of anemia. Postgraduate medicine. 85(5) : 119-22, 127-30, 1989. http://www.ncbi.nlm.nih.gov/pubmed/2648368
  • Denic S, Djulbegovic B, Ridzanovic Z. Optimal timing of bone marrow transplantation in chronic myelogenous leukemia. Period Biol. 91: 391-396, 1989.
  • Ridzanovic Z, Djulbegovic B. Reasons and practice of poor diagnostic testing. Lijec Vjesn. 110: 395-401, 1988.
  • Scepanovic D, Djulbegovic B. Some genetic considerations on Buerger's disease. In: Proceedings of I Yugoslav Congress of Angiology.. : 381-392, 1988.
  • Djulbegović B, Christmas SE, Moore M. Differentiated HL-60 promyelocytic leukaemia cells produce a factor inducing differentiation. Leukemia research. 11(3) : 259-64, 1987. http://www.ncbi.nlm.nih.gov/pubmed/3470575
  • Djulbegovic B, Secerbegovic S. Diagnosis of acute ischaemic heart disease with an aid of a personal computer. Lijec Vjesn. 108: 380-383, 1986.
  • Djulbegović B, Christmas SE, Evans G, Moore M. Studies of the effect of 1,25-dihydroxycholecalciferol on the proliferation and differentiation of the human promyelocytic leukaemia cell line HL-60. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 40(10) : 407-16, 1986. http://www.ncbi.nlm.nih.gov/pubmed/3472610
  • Djulbegović B, Svetina S. Mathematical model of acute myeloblastic leukaemia: an investigation of the relevant kinetic parameters. Cell and tissue kinetics. 18(3) : 307-19, 1985. http://www.ncbi.nlm.nih.gov/pubmed/3857125
  • Kusec Lj, Djulbegovic B, Obradov S et al. Prognostic factors in multiple myeloma. Med Arh. 38: 203-211, 1984.
  • Djulbegovic B, Konjicija A. Mathematical basis of clinical judgement. Med Arh. 38: 245-258, 1984.
  • Serdarevic Dz, Djulbegovic B, Mulabegovic N. Drug effects on laboratory tests. Med Arh. 33: 379-385, 1979.
  • Djulbegovic B, Filipovic S. Studies of lactate dehydrogenase isoenzymes in human tissues. Med pod. 28: 47-52, 1976.
  • Djulbegovic B. Analysis of lactate dehydrogenase isoenzymes in fundus and pyloric stomach mucosa in healthy people and patients suffering from chronic gastritis. Glas Medic. 16: 177-185, 1976.
  • Djulbegovic B, Filipovic S. Electrophoretic analysis of lactate isoenzymes in human tissues. Glas Medic. 15: 12-18, 1975.

Positions Held

  • co-Director (USF Clinical Translational Science Institute, University of South Florida 2008 - 2013)
  • Medical Director (Cancer Registry, H. Lee Moffitt Cancer Center & Research Institute 2005 - 2008)
  • Director (Section on Evidence-based Medicine and Decision Sciences, H. Lee Moffitt Cancer Center & Research Institute 2007 - 2008)
  • Director (Clinical Research, Hematology-Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida 2003 - 2005)
  • Associate Professor (with tenure) (Medicine and Oncology, University of South Florida 1998 - 2003)
  • Director (Fellowship Program in Division of Blood and Bone Marrow Transplant, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida 1999 - 2001)
  • Director (Hemophilia Program, Kentucky Program for Handicapped Children 1994 - 1998)
  • Associate Professor (with tenure) (College of Medicine, University of Louisville 1996 - 1998)
  • Assistant Professor (College of Medicine, University of Louisville 1990 - 1996)

Awards/Honors

  • Editorial Board of the 2013 IMIA selection: BMC Med Inform Decis Mak 2012;12(94):239-47 (The International Medical Informatics Association: Yearbook of Medical Informatics - 2013)
  • BMJ's Minerva's lead story: Nature 2013;500:395-396 (BMJ - 2013)
  • Faculty Outstanding Research Achievement Award (University of South Florida - 2013)
  • New treatments compared to established treatments in randomized trials (Published in The Cochrane Library - 2012)
  • Selected in 1% of top US doctors (US News & World Report - 2012)
  • The Thomas C. Chalmers Award (senior author) (19th Annual Cochrane Colloquium, Madrid - 2011)
  • Selected in 1% of top US doctors (US News & World Report - 2011)
  • Publication Award to the scientist with publication with highest average impact factor (H. Lee Moffitt Cancer Center & Research Institute - 2007)
  • Elected as Fellow (Fellow of the American College of Physicians (FACP) - 2005)
  • The Thomas C. Chalmers Award (VII Cochrane Colloquium: The Best Evidence for Health Care - 1999)
  • First place for the poster "Regret in Clinical Decision Making" (Second Annual Medical Research Competition Research!Louisville - 1997)
  • Best Books in 1993 (for the book by Djulbegovic B. : Reasoning and Decision making in Hematology) (Journal National Cancer Institute - 1994)